News Releases

IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Aug. 13, 2020-- Urovant Sciences (Nasdaq: UROV)   today reported financial results for the three months ended June 30, 2020 . The first quarter of fiscal 2020 saw the Company achieve a number of significant operational milestones as it embarked

IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Aug. 6, 2020-- Urovant Sciences (Nasdaq: UROV)   announced today that it will report 2020 first fiscal quarter financial results after the close of U.S. financial markets on Thursday, August 13, 2020 .

IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Jun. 18, 2020-- Urovant Sciences (Nasdaq: UROV)   today reported financial results for the three months and 2019 fiscal year ended March 31, 2020 . The fiscal fourth quarter of 2019 marked achievement of key milestones for Urovant Sciences ,

IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Jun. 18, 2020-- Urovant Sciences (Nasdaq: UROV) today announced it has entered into an exclusive three-year distribution agreement with Sunovion Pharmaceuticals Inc. (Sunovion) for services to support the commercialization of vibegron, an

IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Jun. 11, 2020-- Urovant Sciences (Nasdaq: UROV)   announced today that it will report fiscal year and fourth quarter 2019 results after the close of U.S. financial markets on Thursday, June 18, 2020 .

Walt Johnston is a proven senior pharmaceutical executive with nearly 30 years’ experience specializing in global strategy. He has extensive P&L experience in delivering significant revenue growth Mr. Johnston spent the last 12 years with Astellas Pharma, most recently as Senior Vice President,

James Hindman , a veteran global and strategic senior financial executive, brings extensive experience in the pharmaceutical, biologics and medical device industries to the Urovant Board Mr. Hindman most recently served as Chief Financial Officer at Allergan until its $70.5B sale to Actavis IRVINE,

IRVINE, Calif. and BASEL, Switzerland --(BUSINESS WIRE)--May 26, 2020-- Urovant Sciences (Nasdaq: UROV) announced today that President and Chief Executive Officer James Robinson will give a presentation at 7:30 a.m. Pacific / 10:30 a.m. Eastern on Tuesday, June 2, 2020 , at the Jefferies Healthcare

52-Week Post Hoc Analysis Shows Vibegron Patients Had Statistically Significant, Sustained Reduction in UUI and Total Incontinence Episodes Compared to Active Control IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--May 14, 2020-- Urovant Sciences (Nasdaq: UROV) announced today that data from

Mr. Robinson will assume the role of President and CEO and continue as a Urovant Board Member Mr. Robinson’s deep experience in the urology and overactive bladder markets makes him ideally suited to succeed Keith Katkin as Urovant prepares for the potential approval and commercial launch of